InvestSMART

Dimerix Limited (ASX: DXB) - Announcements

Current share price for DXB : $0.235 0.005 (2.08%)+

ASX company news and announcements for Dimerix Limited (DXB) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Dimerix Limited (DXB) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Dimerix Limited (DXB), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Dimerix Limited (DXB)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$141 Application for quotation of securities - DXB 17 Jun 2025 3:22PM $0.510 $0.235 fallen by 53.92%
$141 ACTION3 Clinical Trial Milestone Recruitment Update 13 Jun 2025 8:58AM $0.560 $0.235 fallen by 58.04%
$141 Application for quotation of securities - DXB 12 Jun 2025 12:02PM $0.550 $0.235 fallen by 57.27%
$141 Application for quotation of securities - DXB 10 Jun 2025 11:46AM $0.560 $0.235 fallen by 58.04%
$141 Application for quotation of securities - DXB 5 Jun 2025 3:47PM $0.568 $0.235 fallen by 58.59%
$141 Application for quotation of securities - DXB 3 Jun 2025 11:38AM $0.570 $0.235 fallen by 58.77%
$141 1st ACTION3 site in Japan activated and milestone triggered 30 May 2025 8:26AM $0.570 $0.235 fallen by 58.77%
$141 Application for quotation of securities - DXB 29 May 2025 1:28PM $0.570 $0.235 fallen by 58.77%
$141 Notification of upcoming expiry of Listed Options 29 May 2025 9:25AM $0.585 $0.235 fallen by 59.83%
$141 Application for quotation of securities - DXB 27 May 2025 2:02PM $0.610 $0.235 fallen by 61.48%
$141 Application for quotation of securities - DXB 22 May 2025 11:53AM $0.600 $0.235 fallen by 60.83%
$141 Successful planned IDMC review of ACTION3 trial 22 May 2025 8:31AM $0.590 $0.235 fallen by 60.17%
$141 Change in substantial holding 20 May 2025 1:07PM $0.575 $0.235 fallen by 59.13%
$141 Application for quotation of securities - DXB 20 May 2025 1:06PM $0.575 $0.235 fallen by 59.13%
$141 Dimerix to present at Melbourne Twilight Investor Briefing 20 May 2025 9:33AM $0.560 $0.235 fallen by 58.04%
$141 Application for quotation of securities - DXB 16 May 2025 11:31AM $0.610 $0.235 fallen by 61.48%
$141 Application for quotation of securities - DXB 14 May 2025 12:58PM $0.595 $0.235 fallen by 60.50%
$141 Application for quotation of securities - DXB 12 May 2025 1:09PM $0.615 $0.235 fallen by 61.79%
$141 Application for quotation of securities - DXB 8 May 2025 3:19PM $0.715 $0.235 fallen by 67.13%
$141 Dimerix receives initial upfront payment from Amicus 6 May 2025 8:27AM $0.700 $0.235 fallen by 66.43%
$141 Application for quotation of securities - DXB 1 May 2025 2:20PM $0.720 $0.235 fallen by 67.36%
$141 Investor Webinar and Presentation 1 May 2025 9:22AM $0.480 $0.235 fallen by 51.04%
$141 Dimerix Licenses DMX-200 in the US 1 May 2025 9:10AM $0.480 $0.235 fallen by 51.04%
$141 Quarterly Appendix 4C and Activities Report 30 Apr 2025 12:01PM $0.480 $0.235 fallen by 51.04%
$141 Trading Halt 29 Apr 2025 8:31AM $0.480 $0.235 fallen by 51.04%

51 - 75 of 715 results

Page 3 of 29

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.